Business Context and Reporting Period
This Form 8-K filing by REGENXBIO Inc. reports a corporate governance event dated August 15, 2016. The filing details the election of a new director and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Initial Stock Option: 25,000 shares at an exercise price of $12.30 per share.
- Annual Retainer: $35,000 for Board service.
- Committee Retainer: $5,000 for Compensation Committee service.
- Annual Stock Option: Eligible for 12,500 shares upon conclusion of annual meetings starting in 2017.
Material Changes
The material change reported is the appointment of Daniel Tassé as a Class II director and member of the Compensation Committee, effective immediately. The filing notes that Mr. Tassé is considered an independent director under SEC and NASDAQ rules.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding business operations. The primary contingency noted is the acceleration of stock option vesting in the event of a change of control or death. An indemnification agreement was also executed, requiring the Company to indemnify Mr. Tassé to the fullest extent permitted under Delaware law.
Investor Verification Checklist
- Verify the independence status of Daniel Tassé as defined by NASDAQ Global Select Market rules.
- Review the definitive proxy statement filed on April 18, 2016, for full details on the non-employee director compensation program.
- Confirm the vesting schedule terms for the initial 25,000-share option (equal monthly installments over three years).
- Check the press release (Exhibit 99.1) for additional context on the director's background.